Latest NewLimit News & Updates

See the latest news and media coverage for NewLimit. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
NewLimit

Biotechnology company developing epigenetic reprogramming therapies

newlimit.com
Headquarters
South San Francisco, United States
Founded year
2022
Company type
Private company
Number of employees
10–60

Last updated

Latest news about NewLimit

In short: NewLimit secured $435 million to advance cellular reprogramming therapies and prepared for human trials to reverse liver aging.

Company announcements

NewLimit

NewLimit announces January-February 2026 progress

Discovers new reprogramming payloads restoring hepatocyte functions, advances manufacturing of first candidate, builds AI system doubling discovery rate, and develops kidney endothelial model.

NewLimit

NewLimit reviews 2025 reprogramming achievements

Built first preclinical candidate restoring youthful hepatocyte functions, developed AI doubling discoveries per dollar, discovered 30+ payloads, launched vascular program.

Unlock all announcements with a

Media coverage

Inc.

A $435 Million Bet on 'Reversing Aging'

Biotech startup NewLimit secures a major funding round after claiming a 'breakthrough discovery' of a prototype medicine that rewinds cellular aging in the liver.

STAT News

Longevity startup NewLimit raises $435 million ahead of first clinical trial

Allison covers what hot startups are getting up to, and who's financing them. She is also co-host of the weekly biotech podcast, "The Readout Loud...

Unlock all articles with a

Never miss news about NewLimit

Track NewLimit and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NewLimit competitors & trending companies

Browse news for competitors to NewLimit and other trending companies.